« Return to News | Awards & Advancement

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

Dr. Wei-Wu He is currently CEO and chairman of OriGene Technologies. He also is the founder and general partner of Emerging Technology Partners, a life sciences focused venture fund. He has also held positions at Human Genome Sciences, Massachusetts General Hospital and Mayo Clinic. He has been involved in founding and funding over 20 biotech companies throughout his career.

Dr. Tak W. Mak is currently the director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a professor in the department of medical biophysics and department of immunology, University of Toronto. He is best known as the leading scientist of the group that first cloned the genes of the human T-cell antigen receptor. Mak has held director and vice president positions at Amgen and Amgen Institute and has experience as a venture capitalist.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.